Displaying 81 - 100 of 221
FTC Approves Final Order Imposing Conditions on Merger of Fresenius Medical Care AG & KGaA and NxStage Medical, Inc.
A Health Check on COPAs: Assessing the Impact of Certificates of Public Advantage in Healthcare Markets
Statement of Chairman Simons, Commissioner Phillips, and Commissioner Wilson Concerning the Proposed Acquisition of NxStage Medical, Inc. by Fresenius Medical Care AG & Co. KGaA
Statement of Commissioner Chopra In the Matter of Fresenius Medical Care AG & Co. KGaA and NxStage Medical, Inc.
Statement of Commissioner Slaughter In the Matter of Fresenius Medical Care AG & Co. KGaA and NxStage Medical, Inc.
FTC Requires Fresenius Medical Care AG & KGaA and NxStage Medical, Inc. to Divest Bloodline Tubing Assets to B. Braun Medical, Inc. as a Condition of Merger
Prices for Medical Services Vary Within Hospitals, But Vary More Across Them
Statement of Federal Trade Commission Concerning Its Vote to Close the Investigation of a Proposed Transaction Combining Massachusetts Healthcare Providers
Simulating Hospital Merger Simulations
The effects of physician and hospital integration on Medicare beneficiaries’ health outcomes
Why is Distance Important for Hospital Choice? Separating Home Bias from Transport Costs
FTC Approves Fresenius Medical Care AG’s Application for Approval of Proposed Plan to Establish New Outpatient Hemodialysis Clinic
Fresenius Medical Care AG & Co. KGaA, In the Matter of
Tthe FTC required Fresenius Medical Care AG & Co. KGaA to sell 60 outpatient dialysis clinics in 43 local markets under a proposed settlement resolving charges that its acquisition of rival dialysis provider Liberty Dialysis Holdings, Inc. would harm competition in numerous local markets for outpatient dialysis services around the country. According to the FTC, Fresenius's acquisition of Liberty would eliminate head-to-head competition between the firms in the 43 markets at issue, leading to higher prices and reduced quality for dialysis consumers.
Statement by Federal Trade Commission Acting Bureau of Competition Director Bruce Hoffman on the Court Ruling Granting a Preliminary Injunction in the Sanford Health/Mid Dakota Clinic Matter
Letter From Markus H. Meier, Assistant Director, Bureau of Competition, Concerning Crouse Health Hospital's Proposal To Sell Discounted Pharmaceutical Products to the Employees, Retirees, and Their Dependents of Its Affiliate, Dated October 20, 2017
FTC Staff Opinion: Crouse Health Hospital’s Proposed Rx Program Is Exempt from Robinson-Patman Act
FTC Staff Seeks Empirical Research and Public Comments Regarding Impact of Certificates of Public Advantage
Displaying 81 - 100 of 221